Analyst Ratings For CGIX – Cancer Genetics (NASDAQ:CGIX)
Today, CGIX – Cancer Genetics (NASDAQ:CGIX) stock was downgraded by Maxim Group from Buy to Hold with a price target of $6.00.
Some recent analyst ratings include
- 4/3/2018-Maxim Group was Downgraded by analysts at Maxim Group from a “Buy ” rating to a ” Hold” rating. They now have a $6.00 price target on the stock.
- 6/27/2017-Dawson James initiated coverage with a Buy rating.
- 6/26/2017-Benchmark initiated coverage with a Speculative Buy rating.
- 9/26/2016-Rodman & Renshaw initiated coverage with a Buy rating.
Recent Insider Trading Activity For CGIX – Cancer Genetics (NASDAQ:CGIX)
CGIX – Cancer Genetics (NASDAQ:CGIX) has insider ownership of 21.30% and institutional ownership of 17.96%.
- On 12/15/2017 John A Roberts, COO, bought 12,200 with an average share price of $2.00 per share and the total transaction amounting to $24,400.00.
- On 12/8/2017 John Pappajohn, Director, bought 150,000 with an average share price of $1.86 per share and the total transaction amounting to $279,000.00.
- On 8/18/2017 John Pappajohn, Director, bought 86,185 with an average share price of $3.24 per share and the total transaction amounting to $279,239.40.
- On 8/17/2017 John Pappajohn, Director, bought 86,185 with an average share price of $3.24 per share and the total transaction amounting to $279,239.40.
- On 6/12/2017 John Pappajohn, Director, bought 100,000 with an average share price of $3.75 per share and the total transaction amounting to $375,000.00.
- On 5/25/2017 Igor Gitelman, Insider, bought 937 with an average share price of $3.95 per share and the total transaction amounting to $3,701.15.
- On 5/23/2017 Igor Gitelman, Insider, sold 937 with an average share price of $4.02 per share and the total transaction amounting to $3,766.74.
Recent Trading Activity for CGIX – Cancer Genetics (NASDAQ:CGIX)
Shares of CGIX – Cancer Genetics closed the previous trading session at with 1.0499999523162842 shares trading hands.